Horizon Therapeutics (NASDAQ:HZNP) had its price objective increased by Bank of America from $92.00 to $95.00 in a report issued on Monday, BenzingaRatingsTable reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Horizon Therapeutics from $60.00 to $85.00 in a research note on Monday, August 3rd. Guggenheim raised their price target on shares of Horizon Therapeutics from $64.00 to $100.00 in a research report on Thursday, August 6th. Morgan Stanley raised their price target on shares of Horizon Therapeutics from $70.00 to $90.00 and gave the company an overweight rating in a research report on Monday, August 10th. BMO Capital Markets raised their price target on shares of Horizon Therapeutics from $70.00 to $105.00 and gave the company an outperform rating in a research report on Thursday, August 6th. Finally, Jefferies Financial Group raised their price target on shares of Horizon Therapeutics from $47.00 to $51.00 and gave the company a buy rating in a research report on Tuesday, April 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of Buy and a consensus price target of $67.83.
NASDAQ:HZNP opened at $75.12 on Monday. The firm has a market capitalization of $15.33 billion, a P/E ratio of 35.87, a PEG ratio of 0.98 and a beta of 1.24. Horizon Therapeutics has a 1-year low of $23.81 and a 1-year high of $78.93. The company’s fifty day moving average price is $61.78 and its 200-day moving average price is $44.14. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.51 and a quick ratio of 1.45.
Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.04. The firm had revenue of $462.80 million for the quarter, compared to analyst estimates of $333.70 million. Horizon Therapeutics had a net margin of 34.09% and a return on equity of 19.67%. The business’s quarterly revenue was up 44.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.49 earnings per share. Equities analysts anticipate that Horizon Therapeutics will post 2.64 EPS for the current fiscal year.
In other Horizon Therapeutics news, EVP Vikram Karnani sold 2,369 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $50.23, for a total transaction of $118,994.87. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jeff Kent sold 57,215 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $49.94, for a total transaction of $2,857,317.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 209,892 shares of company stock worth $13,208,689. Insiders own 4.30% of the company’s stock.
Large investors have recently bought and sold shares of the company. Captrust Financial Advisors purchased a new position in shares of Horizon Therapeutics in the second quarter worth about $59,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Horizon Therapeutics in the first quarter worth about $105,000. Mirador Capital Partners LP purchased a new position in shares of Horizon Therapeutics in the second quarter worth about $200,000. CSat Investment Advisory L.P. lifted its stake in shares of Horizon Therapeutics by 860.9% in the second quarter. CSat Investment Advisory L.P. now owns 3,738 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 3,349 shares in the last quarter. Finally, Toroso Investments LLC purchased a new position in shares of Horizon Therapeutics in the second quarter worth about $208,000. 90.26% of the stock is currently owned by hedge funds and other institutional investors.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: Back-End Load
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.